How Does Ohtuvayre Work? Mechanism of Action Explained in Plain English

Ohtuvayre (ensifentrine) is described as a "first-in-class" COPD treatment — but what does that actually mean? And how is it different from all the other inhalers and nebulized medications that already exist? In this article, we explain exactly how Ohtuvayre works inside the lungs, in plain language anyone can understand.

The Problem: What Happens in COPD Lungs

In a healthy lung, air flows freely through the airways. In COPD — which includes emphysema and chronic bronchitis — two main problems make breathing difficult:

Airway narrowing: The smooth muscles wrapped around the airways tighten, squeezing the breathing tubes and restricting airflow. This is called bronchoconstriction.

Chronic inflammation: The airway lining is chronically inflamed, which thickens the walls, produces excess mucus, and further reduces airflow.

Most COPD medications target one of these two problems. Long-acting bronchodilators (LABAs and LAMAs) address airway narrowing. Inhaled corticosteroids (ICS) address inflammation. Ohtuvayre is unique because it targets both — in a single inhaled molecule, without steroids.

The Key: Cyclic AMP (cAMP) and Cyclic GMP (cGMP)

To understand how Ohtuvayre works, it helps to know about two molecules: cyclic AMP (cAMP) and cyclic GMP (cGMP). These are chemical messengers inside cells that act as "relaxation signals." When cAMP and cGMP levels are high:

Airway smooth muscles relax → airways open up → easier breathing

Inflammatory cells are suppressed → less lung inflammation

The problem is that the body produces enzymes called phosphodiesterases (PDEs) that break down cAMP and cGMP — reducing these beneficial relaxation signals. In COPD lungs, these enzymes can be overactive, tipping the balance toward tightening and inflammation.

How Ohtuvayre Blocks PDE3 and PDE4

Ohtuvayre (ensifentrine) works by blocking two specific phosphodiesterase enzymes: PDE3 and PDE4.

Blocking PDE3: PDE3 normally breaks down cAMP in airway smooth muscle cells. By blocking PDE3, Ohtuvayre allows cAMP to accumulate — causing the smooth muscle cells to relax. This opens up the airways, making it easier to breathe (bronchodilation).

Blocking PDE4: PDE4 normally breaks down cAMP in immune cells (neutrophils, macrophages, T-cells) that drive airway inflammation. By blocking PDE4, Ohtuvayre allows cAMP to build up in these cells, suppressing their inflammatory activity — reducing lung inflammation without using steroids.

The result is a medication that simultaneously acts as both a bronchodilator and a non-steroidal anti-inflammatory agent — the first inhaled therapy for COPD to achieve both effects in one molecule.

Why Is This Different From Existing COPD Drugs?

Here's how Ohtuvayre's mechanism compares to existing drug classes:

LABAs (e.g., formoterol, salmeterol): Stimulate beta-2 receptors to relax airways — bronchodilation only, no anti-inflammatory effect

LAMAs (e.g., tiotropium): Block muscarinic receptors to relax airways — bronchodilation only, no anti-inflammatory effect

Inhaled corticosteroids (ICS): Reduce inflammation — but no bronchodilation, and carry steroid-related risks

Roflumilast (oral PDE4 inhibitor): Blocks PDE4 to reduce inflammation — but is taken as a pill (not inhaled), and does not inhibit PDE3 (no direct bronchodilation)

Ohtuvayre (dual PDE3/PDE4 inhibitor): Blocks both PDE3 and PDE4 simultaneously — provides bronchodilation AND non-steroidal anti-inflammation in one inhaled molecule

What Did Clinical Trials Show About How Well Ohtuvayre Works?

The FDA approval for Ohtuvayre was based on the Phase 3 ENHANCE-1 and ENHANCE-2 trials, which enrolled 1,553 patients aged 40 to 80 with moderate to severe symptomatic COPD. Key results:

Ohtuvayre significantly improved FEV1 (lung function) compared to placebo in both trials

Mean trough FEV1 improvement at Week 12 was 35 mL greater than placebo (95% CI: 14, 68)

Patients showed meaningful improvements in quality of life measures (E-RS and SGRQ scores)

ENHANCE-2 showed a reduction in moderate-to-severe COPD exacerbations vs placebo

Benefits were seen both as monotherapy and as add-on to existing LABA or LAMA therapy

How Is Ohtuvayre Delivered to the Lungs?

Ohtuvayre is delivered through a standard jet nebulizer — a device that converts the liquid medication into a fine mist that can be inhaled into the lungs. The nebulizer requires no high inspiratory flow rate or complex hand-breath coordination, making it particularly useful for patients with more severe COPD who may struggle with dry powder inhalers.

Once inhaled, ensifentrine acts directly on the lung tissue — targeting the PDE3 and PDE4 enzymes in airway smooth muscle cells and inflammatory immune cells. While some ensifentrine enters the bloodstream (metabolized primarily by CYP2C9 enzymes), its primary therapeutic effects happen locally in the lungs.

For information on dosage and how to use Ohtuvayre, see: What Is Ohtuvayre? Uses, Dosage, and What You Need to Know.

Need help finding a pharmacy that carries Ohtuvayre? medfinder calls pharmacies on your behalf and texts you the results.